If 23andMe is acquired, merges with another company, or goes through bankruptcy, your personal and genetic data may be transferred to the new owner as a business asset.
This analysis describes what 23andMe's agreement states, permits, or reserves. It does not constitute a legal determination about enforceability. Regulatory applicability and practical outcomes may vary by jurisdiction, enforcement context, and individual circumstances. Read our methodology
This clause establishes the operational framework for data continuity during corporate transactions, ensuring genetic and health data classified as business assets remain accessible to successor entities. The provision addresses the status of personal information under standard business acquisition protocols rather than treating it as separately governed by user consent requirements.
The updated privacy statement no longer explicitly directs users to a separate Medical Record Privacy Notice for telehealth services or explains that medical information collected through telehealth is governed by different privacy rules. Previously, the policy stated that users choosing telehealth services coordinated through 23andMe would find healthcare privacy protections described in a separate notice. That reference is now absent from the main privacy statement. Users seeking privacy information specific to telehealth services will need to determine independently whether a separate notice exists or contact 23andMe directly using the provided contact information.
View change record →The updated privacy statement no longer explicitly discloses a separate Medical Record Privacy Notice that previously described how medical information is used, disclosed, and maintained for telehealth services. Users who receive telehealth services coordinated through 23andMe may now lack clear notice of which privacy framework governs their medical records, since the reference to that parallel notice has been removed. The organizational scope change from '23andMe Research Institute' to '23andMe' narrows the explicitly named entities responsible for the policy, though operational impact depends on how these entities actually function.
View change record →The removal of this distinct high-severity provision on data transfer during corporate events reduces clarity on what happens to genetic data in M&A or bankruptcy scenarios.
View full change record →Given 23andMe's publicly reported financial difficulties and bankruptcy filing, this clause has immediate practical relevance — consumers' genetic data could be acquired by an unknown third party with potentially different data practices. Consumers concerned about this should consider deleting their account and requesting sample discard now.
How other platforms handle this
We may disclose certain information, in connection with or during negotiations or closing of any merger, sale of company assets, financing, or acquisition of all or a portion of our business to another company.
We may share your information in connection with, or during negotiations of, any merger, sale of company assets, financing, acquisition, or dissolution, transaction, or proceeding involving all or a portion of our business.
We may share your personal information with our affiliates, meaning entities that control, are controlled by, or are under common control with Consensys. We also share information with service providers who assist in operating our services, subject to confidentiality obligations.
Monitoring
23andMe has changed this document before.
Receive same-day alerts, structured change summaries, and monitoring for up to 25 platforms.
This provision is material to M&A due diligence and implicates CCPA requirements for successor entities to honor existing privacy commitments, as well as FTC guidance on data asset transfers in corporate transactions involving sensitive consumer data.
Full compliance analysis
Regulatory citations, enforcement risk, and due diligence action items.
Free: track 1 platform + weekly digest. Monitor: 25 platforms + same-day alerts. No credit card required.
ConductAtlas detected a major restructuring of Meta’s privacy policy that removed detailed consumer rights disclosures and relocated them to separate documents.
Your genetic data may be transferred to a new owner as a business asset. Here is what the Terms of Service actually say and what you can do right now.
Compliance Governance Intelligence
Need to monitor specific governance provisions?
Compliance includes provision-level monitoring, governance timelines, regulatory mapping, and audit-ready analysis.
Built from archived source documents, structured governance mappings, and historical version tracking.
This clause establishes the operational framework for data continuity during corporate transactions, ensuring genetic and health data classified as business assets remain accessible to successor entities. The provision addresses the status of personal information under standard business acquisition protocols rather than treating it as separately governed by user consent requirements.
Given 23andMe's publicly reported financial difficulties and bankruptcy filing, this clause has immediate practical relevance — consumers' genetic data could be acquired by an unknown third party with potentially different data practices. Consumers concerned about this should consider deleting their account and requesting sample discard now.
No. ConductAtlas is an independent monitoring service. We are not affiliated with, endorsed by, or sponsored by 23andMe.